Magnolol

Magnolol^[1]

Names
IUPAC name 3,3′-Neoligna-8,8′-diene-4,4′-diol
Systematic IUPAC name 5,5′-Di(prop-2-en-1-yl)[1,1′-biphenyl]-2,2′-diol
Other names Dehydrodichavicol 5,5'-Diallyl-2,2'-dihydroxybiphenyl 5,5'-Diallyl-2,2'-biphenyldiol
Identifiers
CAS Number	528-43-8 Y
3D model (JSmol)	Interactive image
ChEMBL	ChEMBL180920 N
ChemSpider	65251 N
ECHA InfoCard	100.127.908
KEGG	C10651 N
PubChem CID	72300
UNII	001E35HGVF Y
CompTox Dashboard (EPA)	DTXSID0044076
InChI InChI=1S/C18H18O2/c1-3-5-13-7-9-17(19)15(11-13)16-12-14(6-4-2)8-10-18(16)20/h3-4,7-12,19-20H,1-2,5-6H2 N Key: VVOAZFWZEDHOOU-UHFFFAOYSA-N N InChI=1/C18H18O2/c1-3-5-13-7-9-17(19)15(11-13)16-12-14(6-4-2)8-10-18(16)20/h3-4,7-12,19-20H,1-2,5-6H2 Key: VVOAZFWZEDHOOU-UHFFFAOYAE
SMILES C=CCC1=CC(=C(C=C1)O)C2=C(C=CC(=C2)CC=C)O
Properties
Chemical formula	C18H18O2
Molar mass	266.340 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). N verify (what is YN ?) Infobox references

Magnolol is an organic compound that is classified as lignan. It is a bioactive compound found in the bark of the Houpu magnolia (Magnolia officinalis) and in M. grandiflora.^[2]

Magnolol is a compound that acts on GABA_A receptors and functions as an allosteric modulator. It has antifungal properties and demonstrates anti-periodontal disease effects in animal models. In cell cultures, magnolol stimulates osteoblasts and inhibits osteoclasts, indicating potential for anti-osteoporosis treatment. It also binds in a dimeric form to PPARγ, acting as an agonist of this nuclear receptor. Additionally, magnolol may interact with cannabinoid receptors, acting as a partial agonist of CB2 receptors with lower affinity for CB1 receptors.

It is known to act on the GABA_A receptors in rat cells in vitro^[3] as well as having antifungal properties.^[4] Magnolol has a number of osteoblast-stimulating and osteoclast-inhibiting activities in cell culture and has been suggested as a candidate for screening for anti-osteoporosis activity.^[5] It has anti-periodontal disease activity in a rat model.^[6] Structural analogues have been studied and found to be strong allosteric modulators of GABA_A.^[7]

Magnolol is also binding in dimeric mode to PPARγ, acting as an agonist of this nuclear receptor.^[8]

Magnolol may interact with cannabinoid receptors, acting as a partial agonist of CB₂ receptors, with lower affinity for the CB₁ receptor.^[9]

• Squires, Richard F.; Ai, Jinglu; Witt, Michael-Robin; Kahnberg, Pia; Saederup, Else; Sterner, Olov; Nielsen, Mogens (1999). "Honokiol and magnolol increase the number of 3H muscimol binding sites three-fold in rat forebrain membranes in vitro using a filtration assay, by allosterically increasing the affinities of low-affinity sites". Neurochemical Research. 24 (12): 1593–602. doi:10.1023/A:1021116502548. PMID 10591411. S2CID 9070185.
• Rycek L, Puthenkalam R, Schnürch M, Ernst M, Mihovilovic MD (2015). "Metal-assisted synthesis of unsymmetrical magnolol and honokiol analogs and their biological assessment as GABAA receptor ligands". Bioorg. Med. Chem. Lett. 25 (2): 400–3. doi:10.1016/j.bmcl.2014.10.091. PMC 4297288. PMID 25510374.